LOGIN  |  REGISTER
Terns Pharmaceuticals
Assertio

Quest Diagnostics Releases 2024 Corporate Responsibility Report

June 25, 2025 | Last Trade: US$182.83 3.88 2.17

SECAUCUS, N.J., June 25, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today published its 2024 Corporate Responsibility Report.

The theme of the report, Care Starts Here, reflects the pivotal role Quest plays in an individual's healthcare, providing insights from laboratory diagnostics to drive well-informed decisions. The report details Quest's accomplishments in 2024 across the company's four strategic pillars of corporate responsibility: health access, employee and community engagement, governance and ethics, and environmental sustainability.  

"Care runs deep in the Quest culture, energizing our more than 55,000 colleagues to deliver on the Quest Purpose, working together to create a healthier world, one life at a time," said Jim Davis, Chairman, CEO and President. "As this year's report highlights, we created several exciting new innovations and programs in 2024 to improve health quality and access, not only for our patients, but also for our employees and the communities we serve. We look forward to building on this momentum throughout 2025 and beyond."

In 2024, Quest:

  • Supported nearly 40 programs through the Quest Diagnostics Foundation with organizations committed to improving clinical and community health outcomes
  • Donated approximately $13 million in corporate giving and Foundation grants to organizations focused on disaster relief, health research and local health initiatives
  • Provided approximately one million donated or discounted test requisitions (which often include several tests)
  • Generated employee and corporate donations for over 650 nonprofits through the company's Employee Matching Gifts program
  • Extended its board of directors by welcoming a new director, Robert Carter, a former Executive Vice President and Chief Information Officer for FedEx®, whose expertise in technology and logistics supports Quest's continuous improvement initiatives focused on quality and efficiency
  • Introduced approximately 50 innovative new testing services focused on improving access across several disease areas, including Alzheimer's disease, certain cancers and HIV
  • Spent approximately $300 million on goods and services from small U.S. businesses
  • Reduced usage of electricity and single-use plastics and continued to transition the company's courier fleet in the U.S. to electric and hybrid vehicles
  • Made progress toward securing International Organization for Standardization (ISO) 14001-2015 certification for environmental management for two additional labs in our Marlborough, Massachusetts. and Lewisville, Texas facilities

To read the full report, click on 2024 Corporate Responsibility Report.

About Quest Diagnostics

Quest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to take action to improve health outcomes. Derived from one of the world's largest databases of de-identifiable clinical lab results, Quest's diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. Quest Diagnostics annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our more than 55,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives and create a healthier world. www.QuestDiagnostics.com.

 

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page